Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma - PubMed
5 days ago
- #multiple myeloma
- #gut microbiota
- #bispecific antibodies
- Antibiotic exposure before bispecific antibody (BsAb) therapy in multiple myeloma (MM) patients is linked to worse clinical outcomes.
- Study shows significantly lower 1-year overall survival (60% vs 77%) and progression-free survival (26% vs 53%) in antibiotic-exposed patients.
- Higher relapse incidence (68% vs 43%) observed in patients with prior antibiotic use.
- Immunoprofiling revealed reduced CD4+ T-cell counts and lower cytokine levels in antibiotic-exposed patients.
- 16S rRNA sequencing showed depletion of SCFA-producing bacteria and lower serum SCFA concentrations in these patients.
- Microbiota composition before BsAb treatment correlated with therapy response and toxicity.
- Findings highlight the need for antibiotic stewardship and microbiota-preserving strategies to improve BsAb therapy efficacy in MM.